JTZ-951 hydrochloride is an orally active HIF prolyl hydroxylase (HIF-PH) inhibitor with potential for the treatment of renal anemia; it promotes endogenous erythropoietin production and regulates the expression of molecules involved in iron metabolism, thereby stimulating erythropoiesis; it is a novel oral therapeutic agent for anemia associated with chronic kidney disease (CKD).